Patents by Inventor Isabel Amat Riera
Isabel Amat Riera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9877917Abstract: The invention provides liposome formulations comprising fragments from a Mycobacterium tuberculosis-complex strain. It also provides a Mycobacterium tuberculosis-complex strain, fragments of which may be incorporated into selected embodiments of the liposome formulation. The invention further provides suspensions and pharmaceutical compositions comprising the liposome formulations. Furthermore, it discloses the use of the liposome formulations for use in a method of treatment of the human or animal body by therapy, in particular for use in a method of treating or preventing tuberculosis, such as in preventing latent tuberculosis or in tuberculosis prophylaxis, optionally in combination therapy. The formulation of this invention contains sucrose and/or has a lower average particle size than conventional liposome-based agents of tuberculosis therapy, resulting in higher bioavailability and efficiency.Type: GrantFiled: January 4, 2012Date of Patent: January 30, 2018Assignee: ARCHIVEL FARMA, S.L.Inventors: Pere J. Cardona Iglesias, Isabel Amat Riera, Blanca Reyes, Ariadna Selga, Mercè Amat
-
Patent number: 9682042Abstract: The invention relates to an agent for the treatment or prevention of an allergic condition, such as asthma, in a mammal. The agent comprises fragments of a Mycobacterium tuberculosis-complex (MTB-C) strain. These particular fragments may be from a virulent MTB-C strain and/or in the form of a liposome composition. The agent may include further components, such as a liposome-forming agent and/or particular proteins from the MTB-C strain. A particular allergic response that may be treated by the agent of the invention is allergic asthma. A pharmaceutical composition comprising the agent is also provided. Administration of the agent described herein significantly attenuates airway hyperresponsiveness, eosinophilia and lymphocytosis in the airways of sensitized animals. The effectiveness of the agent exceeds on all the evaluated parameters the commercial vaccine BCG Danish 1331 Strain.Type: GrantFiled: January 12, 2012Date of Patent: June 20, 2017Assignee: ARCHIVEL FARMA, S.L.Inventors: Pere Joan Cardona Iglesias, Isabel Amat Riera, Blanca Reyes Moreno, Maria Mercè Amat Fabregat
-
Patent number: 9289483Abstract: The invention relates to the use of an immunotherapeutic agent containing cell wall fragments of a virulent strain of Mycobacterium tuberculosis-complex (MTB-C) for the preparation of a drug for the prophylactic treatment of tuberculosis, in which said agent can be obtained using a method comprising the following steps: cultivate the virulent MTB-C strain over a period equal to or greater than three weeks; and, subsequently, homogenate the cell culture in the presence of a nonionic surfactant.Type: GrantFiled: October 17, 2007Date of Patent: March 22, 2016Assignee: ARCHIVEL FARMA, S.L.Inventors: Pere Joan Cardona Iglesias, Isabel Amat Riera
-
Publication number: 20150132364Abstract: The invention relates to an agent for the treatment or prevention of an allergic condition, such as asthma, in a mammal. The agent comprises fragments of a Mycobacterium tuberculosis-complex (MTB-C) strain. These particular fragments may be from a virulent MTB-C strain and/or in the form of a liposome composition. The agent may include further components, such as a liposome-forming agent and/or particular proteins from the MTB-C strain. A particular allergic response that may be treated by the agent of the invention is allergic asthma. A pharmaceutical composition comprising the agent is also provided. Administration of the agent described herein significantly attenuates airway hyperresponsiveness, eosinophilia and lymphocytosis in the airways of sensitized animals. The effectiveness of the agent exceeds on all the evaluated parameters the commercial vaccine BCG Danish 1331 Strain.Type: ApplicationFiled: January 12, 2012Publication date: May 14, 2015Applicant: ARCHIVEL FARMA, S.L.Inventors: Pere Joan Cardona Iglesias, Isabel Amat Riera, Blanca Reyes Moreno, Maria Mercè Amat Fabregat
-
Publication number: 20150050327Abstract: The invention provides liposome formulations comprising fragments from a Mycobacterium tuberculosis-complex strain, it also provides a Mycobacterium tuberculosis-complex strain, fragments of which may be incorporated into selected embodiments of the liposome formulation. The invention further provides suspensions and pharmaceutical compositions comprising the liposome formulations. Furthermore, it discloses the use of the liposome formulations for use in a method of treatment of the human or animal body by therapy, in particular for use in a method of treating or preventing tuberculosis, such as in preventing latent tuberculosis or in tuberculosis prophylaxis, optionally in combination therapy. The formulation of this invention contains sucrose and/or has a lower average particle size than conventional liposome-based agents of tuberculosis therapy, resulting in higher bioavailability and efficiency.Type: ApplicationFiled: January 4, 2012Publication date: February 19, 2015Applicant: ARCHIVEL FARMA, S.L.Inventors: Pere J. Cardona Iglesias, Isabel Amat Riera, Blanca Reyes, Ariadna Selga, Mercè Amat
-
Patent number: 8795719Abstract: The present invention relates to the use of an immunotherapeutic agent having cell wall fragments of a virulent strain of Mycobacterium tuberculosis for the preparation of a drug suitable for the primary prophylaxis of tuberculosis. The immunotherapeutic agent is capable of inducing a protective response that is more effective than the conventional BCG vaccine and reduces the number of viable bacilli in the lungs and in the spleen of individuals recently infected by M. tuberculosis.Type: GrantFiled: September 3, 2009Date of Patent: August 5, 2014Assignee: Archivel Farma, S.L.Inventors: Pere Joan Cardona Iglesias, Isabel Amat Riera
-
Patent number: 8246944Abstract: This invention refers to an immunotherapeutic agent based on cell wall fragments from virulent Mycobacterium tuberculosis strains, to a method for obtaining this immunotherapeutic agent, to pharmaceutical formulations containing it and to its use for the preparation of a drug for the combined treatment of tuberculosis in association with other drugs.Type: GrantFiled: October 29, 2004Date of Patent: August 21, 2012Assignee: Archivel Farma, S.L.Inventors: Pere Joan Cardona Iglesias, Isabel Amat Riera
-
Publication number: 20110268788Abstract: The present invention relates to the use of an immunotherapeutic agent having cell wall fragments of a virulent strain of Mycobacterium tuberculosis for the preparation of a drug suitable for the primary prophylaxis of tuberculosis. The immunotherapeutic agent is capable of inducing a protective response that is more effective than the conventional BCG vaccine and reduces the number of viable bacilli in the lungs and in the spleen of individuals recently infected by M. tuberculosis.Type: ApplicationFiled: September 3, 2009Publication date: November 3, 2011Applicant: ARCHIVEL FARMA, S.L.Inventors: Pere Joan Cardona Iglesias, Isabel Amat Riera
-
Publication number: 20100068258Abstract: The invention relates to the use of an immunotherapeutic agent containing cell wall fragments of a virulent strain of Mycobacterium tuberculosis-complex (MTB-C) for the preparation of a drug for the prophylactic treatment of tuberculosis, in which said agent can be obtained using a method comprising the following steps: cultivate the virulent MTB-C strain over a period equal to or greater than three weeks; and, subsequently, homogenate the cell culture in the presence of a nonionic surfactant.Type: ApplicationFiled: October 17, 2007Publication date: March 18, 2010Applicant: ARCHIVEL FARMA, S.L.Inventors: Pere Joan Cardona Iglesias, Isabel Amat Riera
-
Publication number: 20070269501Abstract: This invention refers to an immunotherapeutic agent based on cell wall fragments from virulent Mycobacterium tuberculosis strains, to a method for obtaining this immunotherapeutic agent, to pharmaceutical formulations containing it and to its use for the preparation of a drug for the combined treatment of tuberculosis in association with other drugs.Type: ApplicationFiled: October 29, 2004Publication date: November 22, 2007Inventors: Pere Cardona Iglesias, Isabel Amat Riera